| Ticker Details |
Eli Lilly & Co.
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$1.12T |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.67 | 1.10%
|
| Avg Daily Range (30 D): |
$20.02 | 1.68%
|
| Avg Daily Range (90 D): |
$18.12 | 1.67%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.29M |
| Avg Daily Volume (30 D): |
2.07M |
| Avg Daily Volume (90 D): |
2.4M |
| Trade Size |
| Avg Trade Size (Sh.): |
107 |
| Avg Trade Size (Sh.) (30 D): |
18 |
| Avg Trade Size (Sh.) (90 D): |
19 |
| Institutional Trades |
| Total Institutional Trades: |
88,319 |
| Avg Institutional Trade: |
$11.06M |
| Avg Institutional Trade (30 D): |
$114.03M |
| Avg Institutional Trade (90 D): |
$111.45M |
| Avg Institutional Trade Volume: |
.07M |
| Avg Institutional Trades (Per Day): |
15 |
| Market Closing Trades |
| Avg Closing Trade: |
$101.27M |
| Avg Closing Trade (30 D): |
$467.37M |
| Avg Closing Trade (90 D): |
$529.89M |
| Avg Closing Volume: |
416.74K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$29.84
|
$7.95
|
$8.27
|
|
Diluted EPS
|
$29.79
|
$7.94
|
$8.25
|
|
Revenue
|
$79.67B
|
$22.97B
|
$19.8B
|
|
Gross Profit
|
$66.44B
|
$19.71B
|
$16.22B
|
|
Net Income / Loss
|
$26.71B
|
$7.1B
|
$7.4B
|
|
Operating Income / Loss
|
$33.6B
|
$9.25B
|
$8.85B
|
|
Cost of Revenue
|
$13.23B
|
$3.27B
|
$3.58B
|
|
Net Cash Flow
|
$5.57B
|
|
|
|
PE Ratio
|
|
|
|
|
|
|
